Zim Laboratories Ltd

Zim Laboratories Ltd has released its Earnings Presentation for the first quarter of Fiscal Year 2027 (Q1 FY27). The presentation details financial performance, including Total Operating Income of ₹942 Mn, a decrease from ₹718 Mn in Q1 FY26. EBITDA stood at ₹34 Mn, down from ₹57 Mn in the prior year's quarter, resulting in a lower EBITDA margin of 3.7% compared to 7.9% in Q1 FY26. The company also reported a Total R&D Spend of ₹82 Mn, which included ₹34 Mn for BE studies and regulatory filings. The presentation covers business mix, R&D and innovation pipeline progress, and shareholding structure.

Zim Laboratories Ltd announced its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors approved the standalone and consolidated results during a meeting held on August 6, 2026. The results were prepared in accordance with Indian Accounting Standard 34 and reviewed by Deloitte Haskins & Sells LLP. The filing also lists the subsidiaries included in the consolidated results.

Zim Laboratories' consolidated Q1 FY27 revenue grew 31.2% YoY to ₹94.18 Cr (from ₹71.76 Cr), but the net loss widened to ₹4.02 Cr from ₹1.87 Cr a year ago, and the company swung from a ₹3.74 Cr profit in Q4 FY26 to this quarter's loss — QoQ revenue itself fell 10.5% from ₹105.27 Cr, consistent with a seasonally stronger Q4. Standalone mirrors the same story: revenue of ₹93.05 Cr against a loss that widened to ₹3.88 Cr from ₹1.69 Cr a year ago. No analyst consensus for this quarter could be located — web searches returned only results for the unrelated NYSE-listed shipping company that shares the ZIM ticker — so the print is assessed against management's own prior guidance rather than street estimates. At the Q4 FY26 concall, management had guided to "margin expansion in the mid-teens" for FY27 as EU GMP CAPA remediation completed and diversified markets scaled, while flagging near-term revenue drag from MENA geopolitical disruption and the EU GMP reinstatement process. This quarter runs counter to that framing on margins: consolidated OPM (EBITDA margin) compressed to 2.6% from 5.9% a year ago and 6.8% in Q4 FY26, even as gross margin (revenue less inventory-adjusted material costs) held roughly flat near 58%. The compression traces to "other expenses," which rose 44.6% YoY to ₹33.08 Cr — outpacing 31.2% revenue growth and rising from 31.9% to 35.1% of revenue — consistent with the compliance/logistics costs management flagged around EU GMP reinstatement and the MENA disruption. Employee costs (+31.3% YoY) and finance costs (+10.3% YoY) grew roughly in line with or slower than revenue and were not the primary drag. The quarter's other developments were largely administrative rather than operational catalysts: the board approved these unaudited results on 6 August, the company allotted 1,09,451 ESOP shares on 13 July, and promoter Dr Anwar Daud raised his stake by 0.15% on 16 June — none bearing directly on this quarter's cost pressure. No separate management press release accompanied the filing to contextualise the print beyond the financial statements. Going forward, the widening loss despite 31% YoY revenue growth means the mid-teens margin-expansion guidance is not yet visible in the numbers, keeping the EU GMP reinstatement timeline and the other-expenses trend as the key items to verify next quarter.

Zim Laboratories Ltd has announced that its Board of Directors will convene on August 6, 2026. The primary agenda for this meeting is to consider and approve the company's Unaudited Financial Results for the quarter ending June 30, 2026. These results will be presented on both a standalone and consolidated basis. Additionally, the company has informed about the closure of the trading window for its securities, effective from July 1, 2026, until August 8, 2026, in compliance with SEBI regulations regarding insider trading.

Zim Laboratories Ltd announced the allotment of 1,09,451 equity shares to eligible employees under the ZIM Laboratories Employee Stock Option Scheme (ESOS 2023). This allotment, approved via circular resolution on July 13, 2026, increases the company's paid-up equity share capital from Rs. 53,54,90,370 to Rs. 53,65,84,880. The new shares, with a face value of INR 10 each, were issued at an exercise price of INR 77.40 per share, realizing Rs. 84,71,507.40. The company confirmed these shares will rank pari-passu with existing equity shares.

Zim Laboratories Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will be closed effective from July 1, 2026, and will reopen 48 hours after the declaration of the company's financial results for the quarter ending June 30, 2026. This is a standard procedure to prevent potential insider trading during periods of sensitive financial information disclosure.

Zim Laboratories Ltd has disclosed an inter-se transfer of equity shares among its promoters. Dr. Anwar Daud acquired 80,000 equity shares, representing 0.15% of the diluted share capital, from Mr. Zulfiquar Kamal. The transaction, valued at INR 107.50 per share, falls under an exemption provided by Regulation 10(1)(a)(ii) of the SEBI SAST Regulations, thus not requiring an open offer. This move adjusts the shareholding percentages between the promoters, with Dr. Daud's stake increasing slightly to 25.05% and Mr. Kamal's decreasing to 2.08%.

Zim Laboratories Ltd has informed the stock exchanges that it has dispatched a letter to its members, providing the weblink to its Annual Report for the Financial Year 2025-26. This action is in compliance with Regulation 36(1)(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The letter is specifically for those members who have not registered their email addresses. The company also announced its 42nd Annual General Meeting (AGM) scheduled for June 29, 2026, to be held via video conferencing. The filing also serves as a reminder for shareholders to update their KYC details as per recent SEBI circulars.

Zim Laboratories Ltd has filed its Annual Report for the Financial Year 2025-26, as per SEBI regulations. The report details the company's performance, strategic priorities for FY27, and its focus on patient-centric drug delivery solutions using Novel Drug Delivery Techniques. Key highlights include addressing EU-GMP remediation, strengthening quality systems, and advancing its differentiated product portfolio. The company also reported strengthening human resources and leadership capabilities with strategic hires in key positions to support global ambitions. The Annual Report is available on the company's website.

Zim Laboratories Ltd has announced its 42nd Annual General Meeting (AGM) to be held on Monday, June 29, 2026, at 11:30 a.m. IST via Video Conferencing. The company has also enclosed the Annual Report for the Financial Year 2025-26 along with the AGM notice. Key agenda items include the adoption of audited financial statements for FY26, re-appointment of a director, ratification of cost auditor remuneration, and approval for director remuneration in case of inadequate profits. The Register of Members and Share Transfer Book will be closed from June 23 to June 29, 2026.